Fibronectin release by systemic sclerosis and normal dermal fibroblasts in response to TGF-beta

J Rheumatol. 1991 Feb;18(2):241-6.

Abstract

To determine whether enhanced matrix synthesis by systemic sclerosis (SSc) fibroblasts in vitro is due to increased responsiveness to transforming growth factor-beta (TGF-beta), fibronectin release by SSc and normal fibroblasts (7 pairs) was measured at various concentrations of TGF-beta. In the absence of TGF-beta, SSc fibroblasts released 30 +/- 22% more fibronectin than normal fibroblasts. While both SSc and normal fibroblasts increased fibronectin release at all concentrations of TGF-beta tested, the percentage increases were not statistically greater for the SSc fibroblasts even though 4 of the SSc fibroblasts strains were selectively sensitive to low concentrations of TGF-beta. TGF-beta increased cell numbers of both SSc and normal strains equally. Our data confirm abnormal regulation of fibronectin gene expression in SSc fibroblasts and suggest increased sensitivity to TGF-beta by some SSc fibroblast strains.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Blotting, Western
  • Cell Division / drug effects
  • Cells, Cultured
  • Dose-Response Relationship, Drug
  • Extracellular Matrix / drug effects
  • Extracellular Matrix / metabolism
  • Fibroblasts / metabolism
  • Fibronectins / genetics
  • Fibronectins / metabolism*
  • Gene Expression Regulation / drug effects
  • Humans
  • Scleroderma, Systemic / metabolism*
  • Scleroderma, Systemic / pathology
  • Skin / cytology
  • Skin / metabolism*
  • Transforming Growth Factor beta / pharmacology*

Substances

  • Fibronectins
  • Transforming Growth Factor beta